VELMENI for DENTISTS 3D just hit a major regulatory milestone in digital dentistry. The U.S. Food and Drug Administration has given 510(k) clearance to the company's AI-powered software. This opens the way for advanced 3D cone-beam computed tomography (CBCT) imaging in dental offices across the U.S.
In 2026, industry reports based on the FDA's AI/ML device list indicated that 1,614 AI-powered medical devices had been authorized in the U.S., with 96.2% cleared through the 510(k) pathway.
With this software, qualified dental professionals can use AI to spot and label structures like the maxilla, mandible, mandibular canal, teeth, maxillary sinuses, temporomandibular joints, and airway. The system rebuilds panoramic and cross-sectional images from CBCT data automatically. This speeds up review and helps with treatment planning, working with specialists, and explaining cases to patients.
For dental CBCT and 3D imaging software in the U.S., the standard regulatory route for most diagnostic AI solutions is the 510(k) process, which requires demonstrating substantial equivalence to a legally marketed predicate device. This pathway is widely used for similar products in the dental imaging sector.
VELMENI for DENTISTS 3D is meant to help, not replace, clinical judgment. The company makes it clear: dental professionals are still responsible for final diagnoses, treatment plans, and patient care. Dr. Dale Miles, DDS, MS, FRCD(C), Oral and Maxillofacial Radiologist and CBCT Advisor to VELMENI, says, "I have seen how responsibly developed artificial intelligence can improve consistency and efficiency in dental imaging review while supporting clinical decision-making."
Dental CBCT imaging is already key for implant planning, endodontic checks, orthodontic work, surgical review, and airway analysis. By adding AI to this process, VELMENI is reaching out to a wide range of dental professionals-general dentists, oral surgeons, orthodontists, prosthodontists, endodontists, and imaging centers. They all stand to gain from faster, more consistent image review and documentation.
VELMENI's regulatory notice repeats that its products are there to assist, not replace, qualified dental professionals. Product availability and regulatory status can differ by market. The software is not a substitute for a full clinical exam or in-person assessment.
VELMENI's FDA clearance for 3D CBCT imaging software marks a turning point for AI in dental diagnostics. By building smart segmentation, visualization, and workflow tools into daily routines, the company is changing what connected dental imaging can be. For practices looking to handle complex imaging tasks more smoothly-without giving up clinical control-this sets a new standard for digital workflow in dentistry.
The announcement puts the spotlight on VELMENI's FDA 510(k) clearance. Still, as of the latest available data, an independent search of the FDA's public AccessData database did not show a separate 510(k) record for a product named VELMENI or VELMENI for DENTISTS 3D. To confirm this clearance, stakeholders would need the specific 510(k) number and device name as listed in the FDA's official records. For full transparency and regulatory accuracy, stakeholders should check the FDA AccessData database for the latest device listings and clearance details.
